BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37075697)

  • 1. Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry.
    Riecke K; Müller V; Neunhöffer T; Park-Simon TW; Weide R; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Wuerstlein R; Denkert C; Decker T; Fehm T; Nekljudova V; Rey J; Loibl S; Laakmann E; Witzel I
    ESMO Open; 2023 Jun; 8(3):101213. PubMed ID: 37075697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
    Laakmann E; Witzel I; Neunhöffer T; Park-Simon TW; Weide R; Riecke K; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Zahm DM; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
    ESMO Open; 2022 Jun; 7(3):100495. PubMed ID: 35653983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.
    Znidaric T; Gugic J; Marinko T; Gojkovic Horvat A; Paulin Kosir MS; Golo D; Ivanetic Pantar M; Ratosa I
    Breast J; 2019 Nov; 25(6):1117-1125. PubMed ID: 31286623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores.
    Riecke K; Müller V; Weide R; Schmidt M; Park-Simon TW; Möbus V; Mundhenke C; Polasik A; Lübbe K; Hesse T; Laakmann E; Thill M; A Fasching P; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Witzel I
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors.
    Berghoff AS; Bago-Horvath Z; Ilhan-Mutlu A; Magerle M; Dieckmann K; Marosi C; Birner P; Widhalm G; Steger GG; Zielinski CC; Bartsch R; Preusser M
    Br J Cancer; 2012 Oct; 107(9):1454-8. PubMed ID: 23047551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
    Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
    Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
    Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
    Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
    Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
    Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Breast cancer brain metastases: clinical and prognostic characteristics of different biological subtypes].
    Zhang T; Li Q; Xu B; Zhang P; Yuan P; Ma F; Wang J; Fan Y
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):697-702. PubMed ID: 25564062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype.
    Arvold ND; Oh KS; Niemierko A; Taghian AG; Lin NU; Abi-Raad RF; Sreedhara M; Harris JR; Alexander BM
    Breast Cancer Res Treat; 2012 Nov; 136(1):153-60. PubMed ID: 22968656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).
    Kim JS; Kim K; Jung W; Shin KH; Im SA; Kim HJ; Kim YB; Chang JS; Kim JH; Choi DH; Park YH; Kim DY; Kim TH; Choi BO; Lee SW; Kim S; Kwon J; Kang KM; Chung WK; Kim KS; Yoon WS; Kim JH; Cha J; Oh YK; Kim IA
    Breast Cancer Res Treat; 2021 Apr; 186(2):453-462. PubMed ID: 33392845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer subtypes and survival in patients with brain metastases.
    Nam BH; Kim SY; Han HS; Kwon Y; Lee KS; Kim TH; Ro J
    Breast Cancer Res; 2008; 10(1):R20. PubMed ID: 18307763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of breast cancer subtypes in elderly patients.
    Bergen ES; Tichy C; Berghoff AS; Rudas M; Dubsky P; Bago-Horvath Z; Mader RM; Exner R; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
    Breast Cancer Res Treat; 2016 May; 157(1):91-9. PubMed ID: 27107570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases.
    Laakmann E; Witzel I; Neunhöffer T; Weide R; Schmidt M; Park-Simon TW; Möbus V; Mundhenke C; Polasik A; Lübbe K; Hesse T; Riecke K; Thill M; Fasching PA; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32998430
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China.
    Li Y; Li Q; Mo H; Guan X; Lin S; Wang Z; Chen Y; Zhang Y; Zhang D; Chen S; Cai R; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Ma F; Xu B
    Breast; 2021 Feb; 55():30-36. PubMed ID: 33310633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.
    Witzel I; Laakmann E; Weide R; Neunhöffer T; Park-Simon TJ; Schmidt M; Fasching PA; Hesse T; Polasik A; Mohrmann S; Würschmidt F; Schem C; Bechtner C; Würstlein R; Fehm T; Möbus V; Burchardi N; Loibl S; Müller V
    Eur J Cancer; 2018 Oct; 102():1-9. PubMed ID: 30099223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
    Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
    Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases.
    Shah AN; Santa-Maria CA; Mukhija D; Shah N; Kang AK; Kumthekar P; Burdett K; Chandra S; Chang J; Tsarwhas D; Woodman J; Jovanovic B; Gerratana L; Gradishar W; Cristofanilli M
    Clin Breast Cancer; 2023 Apr; 23(3):324-329. PubMed ID: 36621430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery.
    Wilson TG; Robinson T; MacFarlane C; Spencer T; Herbert C; Wade L; Reed H; Braybrooke JP
    Clin Oncol (R Coll Radiol); 2020 Jun; 32(6):390-396. PubMed ID: 32131980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.